Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -13K | 0 | 0 | 0 | -1M |
| Operating Income | -46M | -55M | -13M | -14M | -170M |
| EBITDA | -46M | -59M | -14M | -15M | -170M |
| Net Income | -43M | -59M | -15M | -15M | -172M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.30
-2.27% today
1Y Change
+84.37%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kalaris Therapeutics Inc (KLRS) is a Healthcare stock with a market cap of $100.00M and listed on NASDAQ. The stock last traded around $4.30 and up 84.4% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +75.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +75.7%, free cash flow +36.2% with operating margin 0.0% and ROIC -41.1%. Stock Foundry combines KLRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KLRS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KLRS Max Drawdown
-62.80%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for KLRS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$172.0M
-1010.5% YoY
Free Cash Flow
-$106.3M
-987.5% YoY
Revenue Growth
+0.0%
EPS Growth
+75.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -13K | 0 | 0 | 0 | -1M |
| Operating Income | -46M | -55M | -13M | -14M | -170M |
| EBITDA | -46M | -59M | -14M | -15M | -170M |
| Net Income | -43M | -59M | -15M | -15M | -172M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 98M | 118M | 3M | 3M | 202M |
| Total Assets | 122M | 119M | 3M | 4M | 287M |
| Total Liabilities | 43M | 5M | 48M | 34M | 61M |
| Shareholder Equity | 79M | 113M | -45M | -30M | 225M |
| Total Debt | 1M | 0 | 0 | 3M | 30M |
| Net Debt | -97M | -118M | -3M | 194K | -172M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
106M
-987.2% YoY
Capital Expenditures
26K
Free Cash Flow
106M
-987.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.1%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.